The global glycomics market size was estimated at USD 822.5 million in 2018. It is anticipated to expand at a CAGR of 14.7% over the forecast period. Technological advancements are expected to drive the market. Rising investments in research by various government bodies and development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors. In addition, rising focus on glycomics and proteomics research studies is anticipated to propel market expansion in near future.
Rising investments from governments and organizations have enabled academic researchers to develop new glycomics and glycobiology tools. This factor is anticipated to drive the field of glycoscience, thereby driving the overall market. In glycoproteomics, there is a need for advanced analytical methods for studying pathogen and human glycobiology in disease and health.
Hence, there has been a rise in biomedical and proteomics research, leading to the growth of this market. Technological advancements have also contributed to the increased demand for glycomics instruments. Procedures like protein characterizations are evolving into advanced technologies, such as High Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Capillary Electrophoresis (CE) in chemical and biochemical research. These advanced techniques provide rapid and high-sensitivity results.
Pharmaceutical and biotechnology companies are growing with increasing R&D activities, which include glycomics research. For instance, Thermo Fisher Scientific invested around USD 888 million in R&D in 2017. Agilent Technologies spent USD 339 million on R&D in 2017. Moreover, small-scale pharmaceutical companies are also spending more on R&D. This factor is anticipated to accelerate market growth in the years to come.
In 2018, instruments held the largest market share owing to frequent usage in drug discovery and diagnostic testing. In addition, repetitive purchase of reagents and kits is another major factor expected to boost segment growth. Enzymes are estimated to account for a considerable market share in near future due to rising research in cancer therapeutics and diagnosis.
Glycomics uses various research approaches to quantify or define glycome of a tissue, cell, or organism. Alteration such as localization or in the activity of enzymes involved in glycan biosynthesis ultimately results in changing of the final glycan structure. Therefore, apart from genetic markups of individuals, glycans can be analyzed to assess environmentally induced changes. This study can be used in disease diagnosis and drug discovery. This is one of the major factors propelling segment growth.
A large number of research studies have been conducted to commercialize glycoside inhibitors that are known to alter N-linked glycans of cancer cells and viruses. Therapeutic use of these enzymes include direct antiviral, antibacterial, and anti-cancer activities. They aid in treatment of diseases caused by deficiencies such as Tay-Sachs disease and Gaucher disease, and most importantly, diabetes. Thus, among enzymes, glycosidases held the largest market share in terms of revenue. The segment is anticipated to witness a CAGR of 16.1% from 2019 to 2026.
Various research studies indicate that epigenetic regulation of glycans in cancer cells results in formation of new glycan structures. These structures are one of the mechanisms used by cancerous cells to evade immune response in a host. Scientists have designed genetic engineered cell models to understand functions of specific glycan cancer epitopes. These factors are therefore anticipated to propel market growth during the forecast period.
On the basis of end use, academic and research institutes accounted for the largest revenue share in 2018 due to increased R&D investments. Collaborations between major organizations and research institutes are further supporting the segment expansion. The pharmaceutical and biotechnology companies segment is anticipated to register the fastest CAGR during the forecast period owing to increasing R&D investments in drug discovery and development and in other glycobiology based studies.
Increasing adoption of glycan structure data analysis by research centers also contributes to the segment growth. Preference for glycomics for training and educational purposes is another factor contributing to the segment growth. A wide range of applications in drug discovery and development, biomedical research, cell biology, immunology, and biochemistry is expected to drive the market in near future.
On the basis of application, drug discovery and development accounted for the largest market share in 2018. This is primarily owing to extensive R&D and increased government funding for research related to glycomics and proteomics. The other applications segment is anticipated to witness the highest CAGR over the forecast period due to rising clinical trials and R&D expenses incurred by key companies for research. For instance, R&D expenditure of Merck accounted for USD 2.4 billion in 2017.
Research in glycome informatics, which helps in identification and analysis of drug targets and biomarkers, is increasing due to wide application of glycan structure analysis in bioinformatics. Glycomics involves study of functions and structures of glycans in biological systems. Thus, it can be used in personalized medicines for early detection of diseases to select suitable line of treatment. Combining glycomics and genomics helps in diagnosis of congenital disorders of glycosylation including CCDC115-CDG, ATP6AP1-CDG, PGM1-CDG, TMEM199-CDG, and MAN1B1-CDG.
North America accounted for the largest market share in 2018 due to the presence of key pharmaceutical and biopharmaceutical companies including Merck KGaA, Agilent Technologies, Danaher, and Thermo Fisher Scientific. Presence of well-established healthcare infrastructure and accessibility to advanced products have driven the regional market. Moreover, government funding for R&D activities is another key factor boosting the glycobiology market growth in this region.
Asia Pacific is expected to be the second fastest-growing regional market during the forecast period owing to untapped market opportunities. Evolving pharmaceutical and biopharmaceutical industries have resulted in immense growth of glycomics in the region. In addition, investments by Contract Research Organizations (CROs) for the development and production of drugs and biologics are expected to fuel growth of the Asia Pacific glycomics market.
Glycoscience with its significance in modern biotechnology and also its ability to access new and innovative technologies is anticipated to offer bio-based industries in Europe with competitive advantage at a global level. Developments have led to introduction of the European Glycoscience Network (EGSF) to address cross-disciplinary integrated interactions with global glycoscience networks established in U.S.
Latin America is anticipated to witness steady growth owing to rapidly developing economies, presence of leading pharmaceutical companies, and evolving healthcare infrastructure. Brazil is expected to expand at a lucrative CAGR during the forecast period owing to increasing life science-related research and developing healthcare infrastructure.
Some of the key companies in the market include Thermo Fisher Scientific, Inc.; Merck KGaA; Agilent Technologies; Bruker; New England Biolabs; Danaher; Shimadzu Corporation; Takara Bio, Inc.; and ProZyme. Majority of these companies have an extensive product portfolio coupled with strong regional presence.
New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies undertaken by these companies for sustainable growth. For instance, in February 2018, Merck KGaA invested 40 million Euros to enhance their distribution and manufacturing services in the Asian region.
In another instance, in July 2018, Agilent Technologies completed the acquisition of ULTRA Scientific Assets, a company engaged in distribution of certified chemical materials and standards. This acquisition was aimed at providing the company with life sciences solutions, creating a wider consumer base.
Glycomics is a relatively novel technique and research is being conducted on its innovative applications. Therefore, major glycomics market participants are collaborating with academic institutes for the development of newer techniques. For instance, collaboration brought about by Agilent Technologies with the University of Southern California to facilitate researchers in the field of diagnostics, new drug development, and medical devices.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, and MEA
U.S., Canada, U.K., Germany, Spain, France, Italy, Russia, Brazil, Mexico, Argentina, Japan, China, India, South Korea, Singapore, Australia, South Africa, Saudi Arabia, and UAE
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global glycomics market report on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Glycan Labeling Kits
Glycan Purification Kits
Glycan Release Kits
Application Outlook (Revenue, USD Million, 2015 - 2026)
Drug Discovery & Development
End Use Outlook (Revenue, USD Million, 2015 - 2026)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.